The Covid19 contamination figures have started to rise again in recent weeks.
There were more than 75,000 confirmed cases on December 7, for an increase of almost 11% in contaminations in 7 days.
In response to this upsurge, the High Authority for Health (HAS) issued a favorable opinion on Thursday, December 8 for the booster use of two new vaccines: VidPrevtyn Beta from Sanofi/GSK and the Nuvaxovid vaccine from Novavax in adults.
mRNA vaccines remain preferred
These two vaccines are presented as "
effective and useful in meeting the needs of people reluctant to mRNA vaccines and those who have a contraindication
", recalls the press release published on December 8.
These injections are nevertheless to be used as a “
second intention
”: bivalent mRNA vaccines remain preferred by the HAS to guarantee better protection.
The idea: to remobilize the French around the update of the vaccination schedule against Covid19, which "
represents the best weapon to protect people at risk of a severe form of the disease
".
The HAS cites in particular the elderly, individuals with comorbidities, pregnant women... On the other hand, Valneva's vaccine for primary vaccination in adults received an unfavorable opinion from the HAS, in the absence of “
clinical efficacy data
”, and “
direct comparison data
” between this vaccine and “
the vaccines currently preferentially recommended and used in France
”.
Read also Bronchiolitis, flu, Covid-19: can French hospitals cope with a triple epidemic?
This additional dose is recommended three months after the last booster for people over 80 and immunocompromised, and 6 months for everyone else.
And this, regardless of the number of doses already administered.
The HAS is targeting people with an insufficient vaccination schedule: “
to date, only 23% of people aged 80 and over, and 38% of people aged 60-79 are sufficiently protected, HAS calls for mobilization: the reminder is to be carried out now so that it produces its full effect for the end-of-year celebrations.
»
